1010836-56-2

Basic information

• Product Name: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile
• Synonyms: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile
• CAS NO: 1010836-56-2
• Molecular Formula: C7H11NO2
• Molecular Weight: 141.16774
• Mol File: 1010836-56-2.mol

Chemical Properties

• Boiling Point: 299.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(1010836-56-2)
• EPA Substance Registry System: 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile(1010836-56-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1010836-56-2(Hazardous Substances Data)

Usage

Uses

Used in Medicinal and Pharmaceutical Research:
4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications, making it a valuable asset in drug discovery and design processes.
Used in Organic Synthesis:
In the realm of organic synthesis, 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile serves as a building block for the creation of a wide range of chemical derivatives. Its versatility enables chemists to modify its structure to achieve specific properties and functions, broadening its applicability in various chemical reactions and product development.
Used in Drug Development:
4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile is employed as a precursor in the development of innovative pharmaceutical agents. Its unique chemical structure provides a foundation for the design of drugs with novel mechanisms of action, potentially leading to breakthroughs in the treatment of various diseases and conditions.
Used in Chemical Research:
In the field of chemical research, 4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile is used as a subject of study to explore its reactivity, stability, and potential interactions with other molecules. This research contributes to a deeper understanding of its properties and may uncover new applications or methods for its synthesis and modification.
Used in the Chemical Industry:
4-(Hydroxymethyl)tetrahydro-2H-pyran-4-carbonitrile is utilized in various chemical processes and applications within the industry. Its unique structure and functional groups make it suitable for use in the production of specialty chemicals, materials, and other products that require specific properties or functions.

Upstream product

• 362703-30-8 methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate 
• 30431-99-3 4-cyano-tetrahydro-pyran-4-carboxylic acid ethyl ester 

Downstream Products

• 1395997-00-8 methyl 6-(4-((4-cyanotetrahydro-2H-pyran-4-yl)methoxy)-2,6-difluorophenyl)-5-fluoropicolinate 

Relevant articles and documents

Synthesis of Spirocyclic β- and γ-Sultams by One-Pot Reductive Cyclization of Cyanoalkylsulfonyl Fluorides

One-pot intramolecular cyclization of novel sp3-enriched cyanoalkylsulfonyl fluorides into spirocyclic β- or γ-sultams is disclosed. The method relies on nitrile group reduction followed by sulfonylation of amino group thus formed upon mild con

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

IMIDAZOLE DERIVATIVE

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.